Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 17,400 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 17,400 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $8.50, for a total value of $147,900.00. Following the transaction, the insider directly owned 1,393,653 shares in the company, valued at $11,846,050.50. This trade represents a 1.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total value of $235,152.00.

Xeris Biopharma Trading Up 6.8%

Shares of XERS traded up $0.57 during midday trading on Tuesday, reaching $8.94. The company had a trading volume of 3,479,668 shares, compared to its average volume of 1,914,952. Xeris Biopharma Holdings, Inc. has a 1-year low of $4.66 and a 1-year high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The firm has a 50 day simple moving average of $6.65 and a 200-day simple moving average of $6.64. The stock has a market cap of $1.54 billion, a PE ratio of 149.00 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $83.13 million for the quarter, compared to analysts’ expectations of $79.83 million. Research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its stake in shares of Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares during the period. Millennium Management LLC increased its position in shares of Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP purchased a new stake in Xeris Biopharma in the 1st quarter valued at about $170,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.